Table 2.
Baseline values of outcome measures
| Fluvoxamine (n = 17) | Placebo (n = 16) | P-value | |
| VAS Fatigue | 7.40 | 7.45 | 0.91 |
| VAS Pruritus | 3.50 | 1.15 | 0.33 |
| Beck Depression Inventory | 11.0 | 10.5 | 0.45 |
| FFSS | |||
| Physical Domain | 24.0 | 16.5 | 0.25 |
| Cognitive Domain | 15.0 | 9.0 | 0.04 |
| Social Domain | 37.0 | 22.5 | 0.04 |
| MFI | |||
| General Fatigue | 18.0 | 17.5 | 0.78 |
| Physical Fatigue | 16.0 | 14.0 | 0.22 |
| Reduction in Activity | 15.0 | 13.0 | 0.30 |
| Reduction in Motivation | 13.0 | 10.0 | 0.17 |
| Mental Fatigue | 13.0 | 13.0 | 0.90 |
| SF-36 | |||
| Physical Functioning | 65.0 | 70.0 | 0.47 |
| Role Functioning Physical | 25.0 | 25.0 | 0.35 |
| Bodily Pain | 62.0 | 62.0 | 0.55 |
| General Health | 40.0 | 35.0 | 0.63 |
| Vitality | 45.0 | 40.0 | 0.64 |
| Social Functioning | 62.5 | 62.5 | 0.34 |
| Role Emotional Functioning | 100.0 | 66.7 | 0.46 |
| Mental Health | 56.0 | 60.0 | 0.28 |
| Reported Health Transition | 4.0 | 4.0 | 1.00 |
All results are expressed as median scores.